Evidence map›Paper›PMID 36226494›Full record

ArticleHaematologica2023

Variation and impact of polygenic hematologic traits in monogenic sickle cell disease.

Thomas Pincez, Ken Sin Lo, Anne-Laure Pham Hung d'Alexandry D'Orengiani, Melanie E Garrett, Carlo Brugnara, Allison E Ashley-Koch, Marilyn J Telen, Frederic Galacteros, Philippe Joly, Pablo Bartolucci and 1 more

Open access · goldAbstract read
In one paragraph

Article in Haematologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Pleiotropic Effects of Polymorphisms in theInternational journal of molecular sciences · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Thomas PincezMontreal Heart Institute, Montreal, Quebec, Canada; Department of Pediatrics, Division of Pediatric Hematology-Oncology, Charles-Bruneau Cancer Center, CHU Sainte-Justine, Universite de Montreal, Montreal, Quebec.
Ken Sin LoMontreal Heart Institute, Montreal, Quebec.
Anne-Laure Pham Hung d'Alexandry D'OrengianiRed Cell Genetic Disease Unit, Hopital Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris Est, IMRB - U955 - Equipe no 2, Creteil.
Melanie E GarrettDuke Molecular Physiology Institute, Duke University Medical Center, Durham, NC.
Carlo BrugnaraDepartment of Laboratory Medicine, Boston Children's Hospital, Boston, MA.
Allison E Ashley-KochDuke Molecular Physiology Institute, Duke University Medical Center, Durham, NC.
Marilyn J TelenDepartment of Medicine, Division of Hematology, Duke University Medical Center, Durham, NC.
Frederic GalacterosRed Cell Genetic Disease Unit, Hopital Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris Est, IMRB - U955 - Equipe no 2, Creteil.
Philippe JolyUnite Fonctionnelle 34445 'Biochimie des Pathologies Erythrocytaires', Laboratoire de Biochimie et Biologie Moleculaire Grand-Est, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France; Laboratoire Inter-Universitaire de Biologie de la Motricite (LIBM) EA7424, Equipe 'Biologie Vasculaire et du Globule Rouge', Universite Claude Bernard Lyon 1, Comite d'Universites et d'Etablissements (COMUE), Lyon.
Pablo BartolucciRed Cell Genetic Disease Unit, Hopital Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris Est, IMRB - U955 - Equipe no 2, Creteil.
Guillaume LettreMontreal Heart Institute, Montreal, Quebec, Canada; Department of Medicine, Faculty of Medicine, Universite de Montreal, Montreal, Quebec. guillaume.lettre@umontreal.ca.
Assistance Publique – Hôpitaux de Paris · FRDuke Medical Center · USMontreal Heart Institute · CABoston Children's Hospital · USLaboratoire Interuniversitaire de Biologie de la Motricité · FR

Funding

Ribozyme-Mediated Repair of Sickle Beta-Globin RNA and DNAU54HL070769 · NHLBI · DUKE UNIVERSITY · PI TELEN, MARILYN J · 2003 to 2010
$8.4M
Pulmonary Hypertension in SCDR01HL079915 · NHLBI · DUKE UNIVERSITY · PI TELEN, MARILYN J · 2005 to 2008
$6.7M
Genome-Wide Association Studies in Sickle Cell Anemia and in CentenariansR01HL087681 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI STEINBERG, MARTIN H. · 2007 to 2010
$6.0M
GENETIC MODIFIERS OF SEVERITY IN SICKLE CELL ANEMIAR01HL068922 · NHLBI · CHILDREN'S HOSPITAL BOSTON · PI PLATT, ORAH S · 2001 to 2005
$3.6M
Outcome Modifying Genes in Sickle Cell DiseaseR01HL068959 · NHLBI · DUKE UNIVERSITY · PI TELEN, MARILYN J · 2001 to 2005
$3.6M
Identifying novel clinical, genetic and proteomic risk factors for sickle cell nephropathy.R21DK124836 · NIDDK · DUKE UNIVERSITY · PI ASHLEY-KOCH, ALLISON E · 2021 to 2022
$443k
NHLBI NIH HHS R01 HL068922NHLBI NIH HHS R01 HL068959NHLBI NIH HHS R01 HL079915NHLBI NIH HHS R01 HL087681NHLBI NIH HHS U54 HL070769NIDDK NIH HHS R21 DK124836
6 · The paper itself

Abstract

Several of the complications observed in sickle cell disease (SCD) are influenced by variation in hematologic traits (HT), such as fetal hemoglobin (HbF) level and neutrophil count. Previous large-scale genome-wide association studies carried out in largely healthy individuals have identified thousands of variants associated with HT, which have then been used to develop multi-ancestry polygenic trait scores (PTS). Here, we tested whether these PTS associate with HT in SCD patients and if they can improve statistical models associated with SCD-related complications. In 2,056 SCD patients, we found that the PTS predicted less HT variance than in non-SCD individuals of African ancestry. This was particularly striking at the Duffy/DARC locus, where we observed an epistatic interaction between the SCD genotype and the Duffy null variant (rs2814778) that led to a two-fold weaker effect on neutrophil count. PTS for these HT which are measured as part of routine practice were not associated with complications in SCD. In contrast, we found that a simple PTS for HbF that includes only six variants explained a large fraction of the phenotypic variation (20.5-27.1%), associated with acute chest syndrome and stroke risk, and improved the statistical modeling of the vaso-occlusive crisis rate. Using Mendelian randomization, we found that increasing HbF by 4.8% reduces stroke risk by 39% (P=0.0006). Taken together, our results highlight the importance of validating PTS in large diseased populations before proposing their implementation in the context of precision medicine initiatives.

Indexed as

Anemia, Sickle CellStrokeFetal HemoglobinGenome-Wide Association StudyGenotypeHumansMultifactorial InheritanceFetal Hemoglobin

Identifiers

PMID36226494
PMCPMC9973495
OpenAlexW4304845645

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.